Document is current
Any future updates will be listed below
-
Authors
Greteman, Breanna B.
Tomasson, Michael H.
Kahl, Amanda R.
Wahlen, Madison M.
Bates, Melissa L.
Strouse, Christopher
Charlton, Mary E.
-
Funding
Funding for this research was provided by:
National Center for Advancing Translational Sciences (UL1TR002537)
National Cancer Institute (HHSN261201800012I/HHSN26100001)
Holden Comprehensive Cancer Center, University of Iowa (P30CA086862, Mezhir Award Grant CA244271)
American Cancer Society (134524-RSG-20-017-01-CCE)
- License Information
-
More Information
Article History
Received: 13 December 2023
Accepted: 6 November 2024
First Online: 26 November 2024
Declarations
:
: BG, AK, MW, and MC have no conflicts of interest to disclose. MT receives support as PI for clinical trials from Pfizer and Janssen. MT and MB are CEO and CMO at LSF Medical Solutions. CS is the principal investigator of clinical trials from Janssen, Pfizer, Takeda, and Poseida pharmaceuticals and receives funding for work unrelated to this study.
: This study was deemed exempt from Institutional Review Board at the University of Iowa.
: Informed consent was obtained from participants and only deidentified data were analyzed for this study.
